^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR1 V561M

    i
    Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
    Entrez ID:
    2260
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment. (PubMed, Cancer Drug Resist)
    Targeting BCL2 in the resistant cells leads to suppression of leukemia development in mouse models, which potentially provides an opportunity to treat patients that become resistant to FGFR1 inhibitors. In addition, elucidation of molecular mechanisms underlying FGFR1-driven leukemias and lymphomas also provides new targets for combined treatment as another option to bypass the FGFR1 inhibitor resistance and improve patient outcome.
    Journal • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    PTEN deletion • PTEN mutation • FGFR1 rearrangement • FGFR1 V561M
    over3years
    Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma. (PubMed, Mol Genet Genomic Med)
    Similar variant allele frequencies of FGFR1 p.K656E and FGFR1 p.V561M mutations in our patient's tumor suggest that these mutations may have occurred at similar time points. Use of FGFR inhibitors in addition to STAT3 or PI3K/mTOR inhibition may prove a useful strategy in targeting our patient's pilomyxoid astrocytoma.
    Clinical • Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    FGFR1 mutation • FGFR1 V561M
    |
    carboplatin • vincristine